“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: QBiotics
QBiotics is a clinical-stage biotechnology company focused on the development of novel small molecule therapies derived from natural compounds. Its lead asset, tigilanol tiglate, is designed to directly target tumours following local injection, with immune-mediated effects. The company is advancing this programme across multiple solid tumour indications.
QBiotics — 1 video in collection
QBiotics is a clinical-stage biotechnology company focused on the development of novel small molecule therapies derived from natural compounds. Its lead asset, tigilanol tiglate, is designed to directly target tumours following local injection, with immune-mediated effects. The company is advancing this programme across multiple solid tumour indications.
We highlight the key points of QBiotics’ investment story.
For further details, please refer to our latest research on the Edison website.
Get access to the very latest content matched to your personal investment style.